ACTG 364--COMPARISON OF THE VIROLOGIC EFFICACY OF NELFINAVIR
$25,114M01FY2000RRNIH
University Of Pennsylvania, Philadelphia PA
Investigators
Linked publications & trials
Paper 36890337Paper 36599136Paper 35843468Paper 34973459Paper 34743343Paper 34355475Paper 33990615Paper 33840726Paper 33002231Paper 32936969Paper 32860463Paper 32655562Paper 32146126Paper 32139262Paper 31943262Paper 31864822Paper 31505070Paper 31404238Paper 31082876Paper 30974509Paper 30549279Paper 29599296Paper 29563196Paper 29523554Paper 28581155Paper 28408440Paper 28275182Paper 27917600Paper 27465220Paper 27208344Paper 26831489Paper 26821779Paper 26684441Paper 26390278Paper 26241322Paper 26112886Paper 25071758Paper 25010003Paper 24473530Paper 24457946Paper 24158425Paper 24000053Paper 23395246Paper 22474066Paper 22348451Paper 22340269Paper 22300172Paper 22025811Paper 21885493Paper 21732401Paper 21226578Paper 20971975Paper 20887395Paper 20874770Paper 20825464Paper 20718814Paper 20681233Paper 20418726Paper 20138299Paper 19858438Paper 19832791Paper 19631267Paper 19422140Paper 19398283Paper 19247441Paper 19194521Paper 19193611Paper 19176401Paper 19150931Paper 19092163Paper 19090952Paper 19059257Paper 19026292Paper 18988892Paper 18949545Paper 18938181Paper 18788650Paper 18715274Paper 18652094Paper 18617073Paper 18597837Paper 18549994Paper 18549878Paper 18537178Paper 18460483Paper 18447765Paper 18436117Paper 18384906Paper 18365398Paper 18347000Paper 18337568Paper 18323573Paper 18248794Paper 18215538Paper 18212282Paper 18155880Paper 18098228Paper 18049122Paper 18035236Paper 18033754
Abstract
The purpose of this study is three-fold: A. To determine the proportion of subjects who achieve a plasma HIV RNA concentration below the limit of detection (HIV RNA <500 copies/mL) at 16 weeks. B. To determine the absolute change in HIV RNA from baseline to week 16. C. To assess the safety and tolerability of NFV and DMP-266 when uses in combination or separately in nucleoside containing regimens.
View original record on NIH RePORTER →